![](https://qtxasset.com/quartz/qcloud5/media/image/BiomarinShanbally.jpeg?VersionId=AYwDjAdiFtzG9MBerdHb1BZhIRHapGyf)
BioMarin downsizes Roctavian efforts but keeps hemophilia gene therapy for 3 markets
After previously floating the possibility of divesting Roctavian, BioMarin has decided to keep the hemophilia A gene therapy—but with a narrowed focus and cost cuts planned across the drug’s R&D, manufacturing and commercialization support functions. …